AbbVie Plans North Chicago, Illinois, Ingredient Manufacturing Operations
02/27/2026
The investment will include the construction of two new active pharmaceutical ingredient manufacturing facilities to support the production of next-generation neuroscience and obesity-reduction medicines. Production is scheduled to begin in 2029.
“This milestone demonstrates further progress against AbbVie’s $100 billion commitment to U.S. R&D and capital investments over the next decade,” said Robert A. Michael, chairman and chief executive officer, AbbVie. “By strengthening AbbVie’s U.S. manufacturing capabilities, we are well-positioned to support our investment in innovation and enhance our ability to deliver next-generation medicines to patients.”
To support the project the company will receive a tax credit worth an estimated $25 million over 15 years through the state’s Economic Development for a Growing Economy agreement.
“By leveraging our economic development tools, the State of Illinois is supporting AbbVie in their efforts to expand advanced manufacturing, create hundreds of quality jobs, and keep Illinois at the forefront of innovation in next-generation medicines,” noted Illinois Department of Commerce and Economic Opportunity (DCEO) Director Kristin Richards.
"AbbVie’s expansion in Illinois reinforces our state’s standing as a global life sciences leader,” added Illinois Economic Development Corporation President and CEO Christy George. “From world-class research institutions and a highly skilled workforce to a deeply integrated manufacturing and logistics network, Illinois offers the full ecosystem required for biopharmaceutical innovation. We are proud that AbbVie continues to grow its legacy here, advancing breakthrough medicines and creating high-quality jobs that strengthen communities across our state.”
AbbVie discovers, develops, manufactures, and markets medicines and therapies to address health conditions such as immunology, oncology, neuroscience, virology, and beyond. The company’s portfolio includes blockbuster drugs like Humira, Skyrizi, and Rinvoq.
Project Announcements
Japan-Based TOCALO Plans Chandler, Arizona, Operations
04/17/2026
Dakota Bodies Expands Liberty, Missouri, Operations
04/17/2026
Linde Plans Garysburg, North Carolina, Air Separation Operations
04/17/2026
Netherlands-Based Signature Foods USA Plans Easley, South Carolina, Manufacturing Operations
04/16/2026
Lumber Liquidators Plans Lawrenceburg, Tennessee, Headquarters Operations
04/16/2026
Canada-Based Bioriginal Food & Science Plans Grand Junction, Colorado, Operations
04/15/2026
Most Read
-
Economic Developer Role Shifting from Deal-Making to Systems Stewardship
Q1 2026
-
What Companies Need from Modern Manufacturing Sites
Q1 2026
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
Capitalizing on the OBBBA Before the 2026 Cliff
Q1 2026
-
Last Word: Don’t Lose by Winning
Q1 2026
-
Advanced Manufacturing Isn’t a Buzzword—It’s a Different Location Strategy
Q1 2026
-
40th Annual Corporate and 22nd Annual Consultant Site Selection Survey Results
Q1 2026